Kornimate/medical-research-clean huggingface dataset:
weight, energy, lipids, and the liver (well) study

Conditions: Nonalcoholic Fatty Liver

Summary: the research study is a parallel arm, randomized placebo-controlled clinical trial designed to assess changes in hepatic lipid accumulation, visceral adipose tissue and postprandial lipid, markers of inflammation and energy metabolism in participants who consume 3 study foods per day for 16 week, while maintaining their body weight.

the study objectives include: 1. to determine the impact of dietary soybean oil on ectopic liver fat and visceral adipose in adults with nonalcoholic fatty liver disease (nafld) or similar diagnosis 2. to evaluate the effect of soybean oil supplementation on postprandial lipids, markers of inflammation and energy metabolism 3. to measure the strength of the association of change in plasma linoleic acid with changes in ectopic liver fat, visceral adipose, and postprandial lipids, markers of inflammation and energy metabolism 4. to explore emerging mechanistic targets of la-rich soybean oils that are linked with reduced liver fat and better cardiometabolic health

Eligibility criteria:
inclusion criteria: * nonalcoholic fatty liver disease (nafld), nonalcoholic steatohepatitis (nash) or similar * body mass index of 20-55 kg/m2 exclusion criteria: * unstable management of heart failure, heart disease events within 3 months, a need for heart surgeries or procedures, and/or the use of a pacemaker or defibrillator * current or previous diagnosis of severe kidney failure or diseases, some liver and pulmonary diseases * severe or uncontrolled circulatory diseases and autoimmune diseases * current diagnosis of or current treatment of cancer other than non-melanoma skin cancer * current or previous diagnosis of type 1 diabetes * use of vitamin e supplements or actos and glucagon-like peptide-1 medications for less than 1 months prior to enrolling. * gastrointestinal diseases or disorders (including pancreatic and gastric bypass surgery) that would prevent participants from tolerating the study foods * food allergy or intolerances * any dietary restriction where consumption of the study foods, study meals/snack or meal challenge or any ingredient would be contraindicated * use of medications where consuming the food products would be contraindicated * use of supplements high in linoleic acid in the past 4 weeks prior to enrolling * hyperthyroidism * pregnancy and lactation * alcohol or drug abuse * inability to access veins for venipuncture * claustrophobia * metal implants or metallic foreign objects in the body
persistence of hepatitis a antibody in healthy adults ~32 years post vaccination.

Conditions: Hepatitis A

Summary: the goal of this clinical trial is to evaluate the persistence of hepatitis a antibody \~32 years post vaccination in healthy adults. the questions this study will answer are: 1) how long antibody persists and 2) the immune response to an additional dose of vaccine among those with no detectable antibody. participants will be asked to provide a blood specimen. those with no detectable antibody will be offered an additional dose of vaccine. the kinetics of antibody response in this population will be summarized.


Eligibility criteria:
inclusion criteria: * consent obtained * participated in original hepatitis a study in 1991 * no detectable hepatitis a antibody \~32 years after study start exclusion criteria: * receipt of any dose of hepatitis a vaccine other than the hepatitis a vaccine used in the initial studies * history of hepatitis a * receipt of blood transfusion or blood products, including immunoglobulins, within the past 6 months. * receipt of any vaccine within the 14 days before receipt of the additional dose of hepatitis a vaccine or scheduled to receive any vaccine within 30 days after receipt of a booster dose of vaccine.
vapocoolant spray effectiveness on arterial puncture pain: randomized double blind placebo-controlled trial

Conditions: Puncture Site Pain

Summary: this study was aimed to compare pain levels from arterial blood gas (abg) sampling performed with vapocoolant spray in comparison to placebo.

previous studies of vapocoolant sprays for reducing pain were mainly on venopuncture with inconsistent results. there was only one prospective open labeled controlled study on arterial blood gas sampling with ethyl chloride which did not show effectiveness. this study will assess the efficacy and tolerability of a topical alkane vapocoolant spray for arterial puncture in adults in comparison to control spray.

Eligibility criteria:
inclusion criteria: * age of 14 years or older, * needs abg as a part of their diagnosis exclusion criteria: * history of analgesic medication used within 24 hours of enrollment, * any sign of decreased consciousness, * history of skin hypersensitivity, * inability to report a pain score, * history of a known neurological problem that changes pain perception, * history of cold related reactions (e.g. raynaud's phenomenon, cold urticaria), * abnormal allen's test

Keywords: vapocoolant effectiveness arterial puncture
epidemiology of infection in acute myeloid leukemia (aml)

Conditions: Acute Myeloid Leukemia

Summary: in recent years, multiple factors have strongly impacted the epidemiology of infections in patients with acute myeloid leukemia. on the one hand, the availability of new effective antileukemic drugs (i.e. venetoclax, flt-3 inhibitors, cpx-351) have expanded the pharmacological armamentarium. on the other hand, first, many of them inhere drug-drug interactions with azoles and fluoroquinolones, facing clinicians with the choice of whether to administer antimicrobial prophylaxis or not. secondly, there is an increase in infections due to multi-resistant agents from both the bacterial and fungal field. third, the onset of a viral pandemic that had high relevance in these patients in terms of morbidity and mortality. the aim of this survey is to collect information on the largest possible sample of patients with aml during induction/consolidation/relapsed-refractory treatment, regarding bacterial, viral, fungal infections. we will evaluate the incidence of the various types of infection in relation to the type of treatment that patients will undergo, in order to identify what should be the best antimicrobial prophylactic approach in each subset of patients.


Eligibility criteria:
inclusion criteria: * ability to sign the consent form * age ≥18 years * new diagnosis of aml (only cases diagnosed after 01/03/2025), apl are included * patients not elegible to any kind of chemotherapy but only best supportive care (bsc) * aml patients treated with induction treatment, consolidation treatment, or relapsed/refractory (for these latter patients the first diagnosis must not be prior to march 01, 2025) * all kind of infectious diseases, including parasites. * clincally or microbiologically diagnosed infections, including fuo exclusion criteria: * hematological diseases, other than aml * patients with an aml diagnosis prior to march 2025 but who relapsed during the period under examination * patients relapsed after allo or auto-hsct (inclusion of post-transplant patients would create an evaluation bias due to the immunological alterations that the transplant procedure causes)
multi-center clinical trial on corneal morphology analysis in chinese population

Conditions: Cornea

Summary: based on the corneal morphometry instrumentation oculus pentacam, which is commonly used before and after clinical refractive surgery, we will collect the corneal morphological and biologic parameters of the population under refractive surgery screening in refractive surgery centers around the country, and construct corneal morphology database in different living areas of chinese people. based on this, compared with the suspected keratoconus and keratoconus population, the screening criteria and reference standards accord with the characteristics of keratoconus of chinese ethnic will be achieved.

the safety of refractive surgery has always been the focus of attention, keratoconus screening is the most important part for the preoperative examination of refractive surgery. favorable tools and appropriate indicators are the premise of fast and accurate screening, and the corneal morphology from various regions of china have various characteristics, the use of uniform standards developed by foreign screening will always induce a lot of problems, for example, the differences of cornea morphological features between european and american ethnic and chinese race, as well as the corneal morphometric indicators between various regions of china, will cause varying degrees of false-positive or false-negative screening results. based on this, in order to further improve the safety of refractive surgery effectively and to obtain the effective and accurate screening of suspected keratoconus population, this study will be conducted to collect the corneal morphological characteristics database of chinese people from all over the country, and to develop a database of chinese ethnographic characteristics for screening keratoconus indicators and reference valuable to guide clinical screening and surgical design.

Eligibility criteria:
inclusion criteria: * no less than 18 years old, in good health, have no active disease in the body and eye, have permanent resident status and have lived in the local area for at least 5 years (please mark the nation). exclusion criteria: * eye diseases, glaucoma, ocular hypertension, glaucoma patients with normal pressure, fundus lesions, ptosis and other eyelid abnormalities.

Keywords: corneal morphology chinese population corneal curvature corneal thickness higher order aberrations
comparative oral bioavailability study of mt-1303

Conditions: Relapsing-remitting Multiple Sclerosis

Summary: the purpose of this study is to assess the comparative oral bioavailability of a formulation b versus the formulation a of mt-1303.


Eligibility criteria:
inclusion criteria: * caucasian males aged 18 to 55 years at screening. * healthy and free from clinically significant illness or disease as determined by medical history, physical examination, laboratory, and other tests at screening and day -1. * a body weight of ≥60 kilograms (kg) and bmi ranging from 18 to 30 kg/m2 at screening or day -1. exclusion criteria: * presence or history of severe adverse reaction or allergy to any medicinal product or relevant excipient that is of clinical significance. * participated in more than three clinical studies of a new chemical entity in the previous year or participated in a clinical study of any imp within 12 weeks or five half-lives of the imp before the administration of the imp in this clinical study. * clinically relevant abnormal medical history, physical findings, or laboratory values at screening or day -1 that could interfere with the objectives of the study or the safety of the subject, as judged by the investigator. * previous medical history of tuberculosis or in the opinion of the investigator a recurrent medical history of cold sores, pharyngitis, urinary tract infection, diarrhoea/dysentery, chest infections, or fungal infection. * subjects who have received any prescribed systemic or topical medication within 14 days prior to administration of the imp(day 1) unless, in the opinion of the investigator and sponsor, the medication will not interfere with the study procedures or compromise safety. slow release medicinal formulations considered to still be active within 14 days prior to the first dose administration will also be excluded unless, in the opinion of the investigator and sponsor, the medication will not interfere with the study procedures or compromise safety.
pprom erythromycin versus azithromycin

Conditions: Preterm Premature Rupture of Membranes

Summary: preterm premature rupture of membranes (pprom) is treated with an antibiotic, erythromycin or azithromycin, to prolong pregnancy. erythromycin is taken for several days and can result in stomach upset in some patients, causing them to stop taking the medication. therefore, azithromycin is often prescribed instead. azithromycin is usually taken only once and stomach upset is not seen or greatly reduced. the goal of this study is to see if there is a difference between the antibiotic (azithromycin) compared to the antibiotic (erythromycin) in prolonging pregnancy in patients with preterm premature rupture of membranes (pprom). the working hypothesis is that there is no difference in the clinical effectiveness between antibiotic regimens containing te macrolides azithromycin and erythromycin for prolonging latency in pprom.

the current standard regimen for pprom patients between the gestational age of 24 0/7 and 32 0/7 weeks, is to administer ampicillin 2gm iv every 6hours for 48hrs followed by amoxicillin 250mg orally every 8 hours for 5 days, with erythromycin 250mg iv for 48hours followed by 500mg orally every 8hours for 5 days. our study design would be a prospective randomized trial. consented, eligible women will be randomized to receive ampicillin as above plus either azithromycin 1 gm orally at enrollment or erythromycin 250mg iv every 6 hours for 48hours followed by 500mg orally every 8hours for 5 days. those who are unable to tolerate the 1gm of azithromycin within the first 30 minutes of administration, a 1000mg powder suspension will be given. in conjunction with standard protocol, a course of steroids for fetal lung maturity will be administered upon the treating staff's discretion, and all group b beta streptococcus positive patients will be treated.

Eligibility criteria:
inclusion criteria: * pregnant women at least 18 years old * gestational age of 24 0/7 to 32 0/7 weeks * singleton gestation * randomization within 36 hours of rupture of membranes. * cervical dilation less than or equal to 4 cm. exclusion criteria: * known lethal fetal anomaly * vaginal bleeding * maternal or fetal indication for delivery * diagnosis of chorioamnionitis on admission * cervical cerclage in place * placenta previa or other known placental anomalies * use of antibiotic therapy within 5 days. * allergy or other contraindications to erythromycin/azithromycin or steroid use.

Keywords: preterm premature rupture of membranes erythromycin azithromycin
cohort of patients infected with sars-cov2 (covid-19) or suspected of being

Conditions: COVID-19

Summary: on 17th march 2020, 198 193 confirmed cases (7 730 in france) of covid-19 infections and 7 854 deaths (175 in france) have been reported from 8th december 2019 in 157 countries. the rapid increase in cases on french territory has led to the transition of france to level 3 of the epidemic on 14th march 2020. the natural history of the disease is still poorly understood, especially prognostic factors, which are crucial for the best medical care of patients in times of epidemics, when hospital capacities are under pressure. a better knowledge of natural history, of prognostic factors, the development and validation of new diagnostic tests, the evaluation of medical care, will lead to a better medical care of patients infected with covid-19.

the principal goal of the research is to assess the prognostic factors of the progression toward severe forms of the covid-19 infection. the secondary aims of the study are to contribute to answer some of the who research priority goals on covid-19 infections: * description of the natural history of the disease, its different forms, its clinical characterisation, its progression profile, the natural history of the disease linked to patient profiles * evaluation and to comparison of different diagnostic methods, linked to the medical case * description of the progression of the immune response during the infection and related to its outcome * description of the replication and the excretion of the virus * description of the progression of the biological markers during the infection and related to its outcome * identification of the prognostic factors of the evolutive profile, especially if negative * description of the patients care * evaluation of the impact of the different therapeutic managements on the clinical outcome, the immune response, the viral load and the biomarkers. * modeling of the epidemiologic impact * identification of targets for treatment development * analysis of cost data linked to the progression the population will include all patients infected with sars-cov2 ou suspected of being, who are taken care of at hospital. the research is based on the collection of clinical and biological data from routine cares and on the biological analysis of blood samples. the principal goal of the covi-biome ancillary study is to identify gastrointestinal predictive factors for a severe form of the covid-19 infection. the principal goal of the covidog ancillary study is to evaluate the sensibility and the specificity of canine olfactory detection for the volatile organic compounds of sars-cov2.

Eligibility criteria:
inclusion criteria: * age ≥ 18 * patient admitted in an emergency unit or hospitalized, infected with sars-cov2 or suspected of being (the recruitment can occured during acute episode or during a follow-up visit) * written informed consent or emergency procedure * affiliated to health insurance system exclusion criteria: * refusal of participation * patient under justice protection measure except guardianship and trusteeship

Keywords: covid-19 cohort prognostic factors severe forms
detection of germline and somatic pathogenic variants in patients with de novo metastatic breast cancer

Conditions: Metastatic Breast Cancer

Summary: to determine somatic and germline pathogenic variants in patients with denovo metastatic breast cancer in order to map the molecular/genetic characteristics of dn- mbc aiming in comprehending the biology and highlighting potential novel treatment options for the disease.

the value of this study is based on the fact that dn-mbc is rare, seems to be different from early and relapsed breast cancer and has not been studied as distinct disease. to achieve the objective of this study blood and tissue sample from patients diagnosed with dn-mbc will be further analyzed using next generation sequencing (ngs), in order to map the molecular/genetic characteristics of dn-mbc and to detect germline and somatic pathogenic variants. all the results will be associated with the clinicopathological characteristics of the patients.

Eligibility criteria:
inclusion criteria: 1. signed informed consent for the provision of the biological material for research purposes 2. diagnosis of de novo mbc (histologically confirmed) 3. age \>18 years 4. blood samples 5. tumor tissue block from at least on disease site, primary (preferably) or metastatic exclusion criteria: inadequate mbc tissue
the use of oral steroids in the treatment of cellulitis

Conditions: Cellulitis; Erysipelas

Summary: the prevalence of cellulitis in society is very high, as much as 3% of visits to emergency departments are for the treatment of this disease. the treatment of cellulitis varies depending on the severity. low severity cases are treated with pain control and antibiotics by mouth and high severity are treated with antibiotics intravenously and pain control. the investigator's hypothesis is to see if the addition of steroids, which are known to decrease inflammation, will decrease the length of the disease process. if so, it will decrease the length of stay if iv antibiotics are needed, it will decrease duration of days out of work and decrease the overall pain control required and therefore patient satisfaction.

the incidence of cellulitis is about 24.6 cases per 1000 person-years, which is an estimate, since cellulitis is not a reportable disease. in some emergency departments up to 3% of visits are for cellulitis. depending on the severity of the disease, some are treated as outpatients, and others are admitted for iv antibiotics. in some emergency departments cases of cellulitis are treated in an observation area for 23 hours with doses of iv antibiotics. my proposed research is to see if the addition of one dose of prednisone the treatment will decrease the inflammatory reaction enough to decrease length of stay and treatment and increase patient satisfaction.

Eligibility criteria:
inclusion criteria: * 18-70 years old * signs/symptoms of cellulitis exclusion criteria: * steroid use in last 2 weeks * hx of adrenal insufficiency * suspicion for dvt or abcess * systemic signs of sepsis * icu admission

Keywords: prednisone cellulitis erysipelas steroids oral
flow versus oxygenation in acute respiratory failure

Conditions: Respiratory Failure

Summary: high flow nasal oxygen therapy has been widely used but guidelines as to the optimal starting flow rate and oxygen percentage are not available. prolonged exposure to an inappropriately high oxygen concentration should be avoided as there is increasing evidence that the production of oxygen free radicals can lead to lung damage. this pilot dose finding study will determine the optimal flow rate and oxygen concentration using hfno2 for patients with respiratory failure requiring low, medium or high oxygen concentration from conventional low flow devices. an assessment will also be made of comfort and compliance with hfno2.

the study will recruit a total of between 180 and 270 patients across three hospital sites mainly from high dependence units. the patients recruited will be stratified into 3 groups according to their oxygen (o2) requirements at recruitment (low, medium and high). all recruited patients will then be given supplementary o2 using the optiflow system. patients from all three recruitment oxygen requirements (low, medium and high) will be randomised to 30 litres, 45 litres or 60 litres per minute with initial a fractional inspired o2 concentration(fio2) of 0.90 (90% oxygen). the fio2 is then decreased in 0.05 increments every 5 minutes and the minimum oxygen saturation recorded until it reaches 94%. end points: minimal fio2 required to maintain saturation above 94% for patients with low, medium and high recruitment oxygen requirements for 30 litres, 45 litres and 60 litres per minute. use kruskal wallis to compare the median fio2 requirements of those patients who recruited with low, medium and high o2 requirement. obtain dose response curve 02 saturation against fio2 for 3 different flow rates for each of the recruitment 02 requirements and use regression modelling to find best fit dose fio2 response o2 saturation curves patient satisfaction scores and number of patients unable to tolerate the three flow rates in each of the three starting groups and flow rates.

Eligibility criteria:
inclusion criteria: patient aged 18-80 at time of recruitment to study) able to give their own consent (4 "a" test score of 0 if capacity questionable) acute respiratory failure but no significant deterioration in the previous hour receiving conventional oxygen therapy (hudson, venturi, non-rebreathing mask or equivalent) up to a maximum of 90% oxygen saturation ≥ 94% and respiratory rate ≤30 exclusion criteria: type ii respiratory failure (chloride ≤95 and bicarbonate ≥35, on an arterial blood gas or venous sample within 4 weeks) chronic respiratory disease limiting functional capacity (mrc breathlessness grade iv or v) pregnancy heart failure (nyha grade iii or iv) decreased gcs cardiovascular instability (systolic bp ≤90 or heart rate ≥130) pulmonary embolism unable to give informed consent contraindication to receiving high flow nasal oxygen * nasal obstruction * previous bleomycin administration * base of skull fracture